RAC - Charts & Price Action, page-1447

‘Prophylactic’ use , or Treatment / maintenance / Suppression of a patient’s cancer — prescribed use .
Part of an individual’s treatment regime , & would be part of an individual’s cancer management , in conjunction with hospital oncology monitored or acute treatment :
• at lower dose &
• at a standard dose (eg. for weight / age ) &
• relatively safely .
( as at such a low dose - it is totally different to bisantrene as a regular higher dosed chemotherapeutic agent .)
** Low dose use - not causing side effects in any way , like as if used for chemotherapy treatment .

This is the way that it would be possible . And the reason that it is compelling .
* The Low Dose *
* Consistent between individuals * .

Prophylactically- no not like taking a regular medication though. Really it would be prescribed more on an individual basis .

It has been an excellent discovery for Race Oncology and RAC holders .

*Bisantrene - potential for bisantrene to control the growth of , and to suppress FTO Protein & it’s expression from occurring -
increased FTO Protein being significantly associated with a broad % of , and broad range and type of cancers in some individuals .
( as seen in the table of FTO protein relevant cancers )

I don’t think we quite want to be putting bisantrene into our daily drinking water however .